$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

$pbio Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223029724 Filed on August 21, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$413.0K	$512.0K	$498.1K
YoY Change	186.74%	2.78%	-18.19%
Cost Of Revenue	$229.5K	$256.6K	$302.1K
YoY Change	81.82%	-15.07%	5.4%
Gross Profit	$183.5K	$255.4K	$196.0K
YoY Change	929.46%	30.31%	-39.18%
Gross Profit Margin	44.44%	49.88%	39.35%
Selling, General & Admin	$1.188M	$1.056M	$924.9K
YoY Change	6.18%	14.2%	29.88%
% of Gross Profit	647.27%	413.58%	471.9%
Research & Development	$288.3K	$280.4K	$172.7K
YoY Change	9.9%	62.36%	-32.66%
% of Gross Profit	157.1%	109.81%	88.13%
Depreciation & Amortization	$24.34K	$28.12K	$27.11K
YoY Change	321.11%	3.73%	-6.84%
% of Gross Profit	13.26%	11.01%	13.83%
Operating Expenses	$1.476M	$1.337M	$1.098M
YoY Change	6.89%	21.78%	13.32%
Operating Profit	-$1.293M	-$1.082M	-$901.6K
YoY Change	-5.17%	19.95%	39.5%
Interest Expense	$4.339M	$5.880M	$1.836M
YoY Change	113.31%	220.31%	-47.94%
% of Operating Profit
Other Income/Expense, Net	-$4.337M	-$5.841M	-$2.015M
YoY Change	39.96%	189.93%	-50.85%
Pretax Income	-$5.630M	-$6.923M	-$2.916M
YoY Change	26.17%	137.38%	-38.54%
Income Tax
% Of Pretax Income
Net Earnings	-$5.630M	-$6.923M	-$2.916M
YoY Change	26.17%	137.38%	-38.54%
Net Earnings / Revenue	-1363.18%	-1352.09%	-585.45%
Basic Earnings Per Share	-$0.29	-$0.57	-$0.32
Diluted Earnings Per Share	-$0.29	-$0.57	-$278.7K
COMMON SHARES
Basic Shares Outstanding	17.76M shares	16.77M shares	10.46M shares
Diluted Shares Outstanding	21.72M shares	19.47M shares	10.46M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.260K	$24.98K	$121.6K
YoY Change	-97.72%	-79.45%	160.71%
Cash & Equivalents	$5.263K	$24.98K	$121.6K
Short-Term Investments
Other Short-Term Assets	$219.3K	$281.0K	$228.3K
YoY Change	0.37%	23.12%	4.15%
Inventory	$467.2K	$553.7K	$1.356M
Prepaid Expenses
Receivables	$329.3K	$189.0K	$316.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.021M	$1.049M	$2.022M
YoY Change	-49.01%	-48.14%	45.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$91.41K	$93.39K	$101.8K
YoY Change	-18.3%	-8.26%	-48.39%
Goodwill
YoY Change
Intangibles	$252.4K	$274.0K	$360.6K
YoY Change	-30.0%	-24.0%
Long-Term Investments	$77.92K	$83.88K	$60.60K
YoY Change	50.05%	38.41%	-77.93%
Other Assets
YoY Change
Total Long-Term Assets	$581.2K	$627.1K	$864.7K
YoY Change	-30.65%	-27.48%	-5.91%
TOTAL ASSETS
Total Short-Term Assets	$1.021M	$1.049M	$2.022M
Total Long-Term Assets	$581.2K	$627.1K	$864.7K
Total Assets	$1.602M	$1.676M	$2.887M
YoY Change	-43.59%	-41.95%	25.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.063M	$912.2K	$552.7K
YoY Change	74.75%	65.05%	-12.11%
Accrued Expenses	$3.166M	$2.914M	$2.533M
YoY Change	13.08%	15.03%	-4.52%
Deferred Revenue
YoY Change
Short-Term Debt	$20.90M	$19.10M	$17.59M
YoY Change	11.0%	8.55%	41.21%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$29.96M	$26.54M	$29.75M
YoY Change	-7.23%	-10.78%	24.18%
LONG-TERM LIABILITIES
Long-Term Debt	$162.5K	$163.2K	$150.0K
YoY Change	8.35%	8.79%	-71.54%
Other Long-Term Liabilities	$81.93K	$86.81K	$203.0K
YoY Change	-52.34%	-57.23%	58.52%
Total Long-Term Liabilities	$244.5K	$250.0K	$353.0K
YoY Change	-24.06%	-29.18%	-46.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.96M	$26.54M	$29.75M
Total Long-Term Liabilities	$244.5K	$250.0K	$353.0K
Total Liabilities	$30.20M	$26.79M	$30.10M
YoY Change	-7.4%	-10.99%	22.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$158.5M	-$152.2M	-$124.0M
YoY Change	22.92%	22.73%
Common Stock	$234.0K	$195.9K	$107.0K
YoY Change	91.48%	82.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$28.60M	-$25.12M	-$27.21M
YoY Change
Total Liabilities & Shareholders Equity	$1.602M	$1.676M	$2.887M
YoY Change	-43.59%	-41.95%	25.16%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.630M	-$6.923M	-$2.916M
YoY Change	26.17%	137.38%	-38.54%
Depreciation, Depletion And Amortization	$24.34K	$28.12K	$27.11K
YoY Change	321.11%	3.73%	-6.84%
Cash From Operating Activities	-$733.8K	-$899.2K	-$1.242M
YoY Change	-30.32%	-27.6%	45.47%
INVESTING ACTIVITIES
Capital Expenditures	$7.500K	$0.00	-$3.750K
YoY Change	-147.29%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$7.500K	$0.00	-$3.750K
YoY Change	-52.71%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	712.7K	685.1K	1.248M
YoY Change	-39.51%	-45.12%	46.91%
NET CHANGE
Cash From Operating Activities	-733.8K	-899.2K	-1.242M
Cash From Investing Activities	-7.500K	0.000	-3.750K
Cash From Financing Activities	712.7K	685.1K	1.248M
Net Change In Cash	-28.60K	-214.1K	2.770K
YoY Change	-126.16%	-7827.44%	-170.84%
FREE CASH FLOW
Cash From Operating Activities	-$733.8K	-$899.2K	-$1.242M
Capital Expenditures	$7.500K	$0.00	-$3.750K
Free Cash Flow	-$741.3K	-$899.2K	-$1.238M
YoY Change	-28.53%	-27.38%	45.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000830656
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants		usd
	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants		usd
	PBIO	Loss On Extinguishment Of Accrued Liabilities And Debt LossOnExtinguishmentOfAccruedLiabilitiesAndDebt		usd
	PBIO	Common Stock And Warrants Issued For Debt Extension CommonStockAndWarrantsIssuedForDebtExtension		usd
	PBIO	Preferred Stock Issued For Debt Extension PreferredStockIssuedForDebtExtension		usd
	PBIO	Preferred Stock Issued For Services PreferredStockIssuedForServices		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption		usd
	PBIO	Preferred Stock Issued With Debt PreferredStockIssuedWithDebt		usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt		usd
	PBIO	Conversion Of Debt Accrued Interest And Accrued Dividend For Preferred Stock ConversionOfDebtAccruedInterestAndAccruedDividendForPreferredStock		usd
	PBIO	Conversion Of Common Stock For Preferred Stock ConversionOfCommonStockForPreferredStock		usd
	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock		usd
CY2023Q1	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023Q2	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock		usd
CY2023Q2	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023Q2	PBIO	Stock Issued During Period Value Conversion Of Common Stock To Preferred Stock StockIssuedDuringPeriodValueConversionOfCommonStockToPreferredStock		usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent		usd
CY2022Q2	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38185
	dei	Entity Registrant Name EntityRegistrantName	PRESSURE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MA
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-2652826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Norfolk Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South Easton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02375
	dei	City Area Code CityAreaCode	(508)
	dei	Local Phone Number LocalPhoneNumber	230-1828
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17762146	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24975	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3865	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	189015	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	295374	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	913019	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	553688	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	686383	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	281014	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	257527	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	1048692	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1243149	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	83883	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	63638	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	93393	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103351	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	175750	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	274038	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	317308	usd
CY2023Q2	us-gaap	Assets Assets	1675756	usd
CY2022Q4	us-gaap	Assets Assets	2009541	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	912230	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	637238	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	288187	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	167247	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2560269	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2497762	usd
CY2023Q2	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	3316693	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	10803983	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	302037	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58242	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	16578261	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
CY2023Q2	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	171103	usd
CY2022Q4	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2023Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1895750	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	621802	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	634885	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65640	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	26540869	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34404166	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	163175	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	80906	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5902	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1822	usd
CY2023Q2	us-gaap	Liabilities Liabilities	26790852	usd
CY2022Q4	us-gaap	Liabilities Liabilities	34695912	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	95	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	95	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19585905	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19585905	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13682910	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13682910	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	195859	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136829	usd
CY2023Q2	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	35684321	usd
CY2022Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31995762	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	91235400	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69006145	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152230771	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133826205	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-25115096	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1675756	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2009541	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	511803	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498137	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1252403	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978137	usd
CY2023Q2	us-gaap	Revenues Revenues	511803	usd
CY2022Q2	us-gaap	Revenues Revenues	498137	usd
	us-gaap	Revenues Revenues	1252403	usd
	us-gaap	Revenues Revenues	978137	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	256599	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	302141	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	615227	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	616504	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	280446	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	172726	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	716092	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	454315	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	154014	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	129434	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	380029	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	195896	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	902265	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	795466	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4260321	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1699351	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	1593324	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	1399767	usd
	us-gaap	Costs And Expenses CostsAndExpenses	5971669	usd
	us-gaap	Costs And Expenses CostsAndExpenses	2966066	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1081521	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-901630	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4719266	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1987929	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	5879653	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	1835589	usd
	us-gaap	Interest Expense InterestExpense	9773339	usd
	us-gaap	Interest Expense InterestExpense	4414750	usd
CY2023Q2	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	12184	usd
CY2022Q2	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-18510	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	20245	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	628	usd
CY2023Q2	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	28314	usd
CY2022Q2	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-165277	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	687591	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-755127	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2027	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4668	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4232	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1155	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5841182	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2014708	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9061271	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5168094	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6922703	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2916338	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13780537	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7156023	usd
CY2023Q2	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants	3626950	usd
	PBIO	Deemed Dividends On Extension Of Warrants DeemedDividendsOnExtensionOfWarrants	3626950	usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	565272	usd
CY2022Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	431708	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	997079	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	863857	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11114925	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3348046	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18404566	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8019880	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19471057	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19471057	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10462520	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10462520	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17629225	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17629225	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10029068	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10029068	shares
	us-gaap	Net Income Loss NetIncomeLoss	-13780537	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7156023	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	687591	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10000	usd
	PBIO	Noncash Lease Expense NoncashLeaseExpense	106345	usd
	PBIO	Noncash Lease Expense NoncashLeaseExpense	53884	usd
	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	3001680	usd
	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	1561973	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	56228	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	62207	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1825243	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1457204	usd
	PBIO	Loss On Extinguishment Of Accrued Liabilities And Debt LossOnExtinguishmentOfAccruedLiabilitiesAndDebt	755127	usd
	PBIO	Common Stock And Warrants Issued For Debt Extension CommonStockAndWarrantsIssuedForDebtExtension	-1521573	usd
	PBIO	Preferred Stock Issued For Debt Extension PreferredStockIssuedForDebtExtension	1397000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1565798	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96557	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	20245	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	628	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1653344	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	185261	usd
	PBIO	Preferred Stock Issued For Services PreferredStockIssuedForServices	505700	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-106359	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	162050	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-132695	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	208122	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	23487	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-194363	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	274992	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	24767	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	120940	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	119422	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-135549	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-53884	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1058126	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1081750	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1321386	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1998192	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4890	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4890	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	81111	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17443	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3499000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2209750	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1909681	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1288100	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	123400	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	464500	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2353536	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	865367	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	148500	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	209000	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1915660	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	913086	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1345496	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1992340	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21110	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10742	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24975	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121569	usd
	us-gaap	Interest Paid Net InterestPaidNet	1064266	usd
	us-gaap	Interest Paid Net InterestPaidNet	515210	usd
	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption	473027	usd
	us-gaap	Stock Issued1 StockIssued1	1244425	usd
	us-gaap	Stock Issued1 StockIssued1	178328	usd
	PBIO	Preferred Stock Issued With Debt PreferredStockIssuedWithDebt	539487	usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	87436	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	162528	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	215277	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	997079	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	863857	usd
	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	5379	usd
	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	44	usd
	PBIO	Conversion Of Debt Accrued Interest And Accrued Dividend For Preferred Stock ConversionOfDebtAccruedInterestAndAccruedDividendForPreferredStock	10017212	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	509033	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	350500	usd
	PBIO	Conversion Of Common Stock For Preferred Stock ConversionOfCommonStockForPreferredStock	6240	usd
	PBIO	Extension Of Warrants For Series Aa Preferred Stock ExtensionOfWarrantsForSeriesAaPreferredStock	3626950	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81111	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1430244	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431807	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1419335	usd
CY2023Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	61609	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	509033	usd
CY2023Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	102435	usd
CY2023Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1705234	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1029939	usd
CY2023Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	1087751	usd
CY2023Q1	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	100000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6857834	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-32449321	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	565272	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	135554	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	172400	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	491634	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10017212	usd
CY2023Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	60093	usd
CY2023Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1296446	usd
CY2023Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	156674	usd
CY2023Q2	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	50000	usd
CY2023Q2	PBIO	Stock Issued During Period Value Issued Preferred Stock For Services StockIssuedDuringPeriodValueIssuedPreferredStockForServices	505700	usd
CY2023Q2	PBIO	Stock Issued During Period Value Issuance Of Preferred Stock For Debt Extension StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension	1397000	usd
CY2023Q2	PBIO	Preferred Stock Issued For Debt Settlement PreferredStockIssuedForDebtSettlement	539487	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6922703	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-25115096	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q1	PBIO	Cumulative Effect Period Of Adoption Adjustment CumulativeEffectPeriodOfAdoptionAdjustment	-473027	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64483	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	432149	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	77700	usd
CY2022Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	39761	usd
CY2022Q1	PBIO	Warrants Issued For Debt Extension WarrantsIssuedForDebtExtension	132537	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	472900	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	350500	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	64256	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1173458	usd
CY2022Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	142480	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	87436	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239685	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-24748311	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32074	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431708	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67800	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	191303	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	151021	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	388515	usd
CY2022Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	35848	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2916338	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-27212353	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	258196	usd
	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zT0ylqR0ri2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zqWF5w6yAgcf">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2728243	usd
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2255216	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	111650	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	146546	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	106345	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	53884	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M2D
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q2	us-gaap	Revenues Revenues	512000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1252000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	512000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1252000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	512000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1252000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978000	usd
CY2023Q2	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	189000	usd
CY2022Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	295000	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	64000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	60000	usd
CY2023Q2	PBIO	Extended Warranty Service ExtendedWarrantyService	64000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zqetK6Hz6kug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zdPDWUwB4Cl9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zngg3VX0gGi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three and six months ended June 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zMLzjJK89iyb" style="display: none">Schedule of Customer Concentration Risk Percentage</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zh3fWucJUmNb" style="width: 11%; text-align: right" title="Concentration credit risk percentage">70</td><td style="width: 1%; text-align: left"><p style="margin: 0">%</p></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zE04OmqYt6ii" style="width: 11%; text-align: right" title="Concentration credit risk percentage">69</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhWOVauPwJEe" style="width: 11%; text-align: right" title="Concentration credit risk percentage"><p style="margin: 0">55</p></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zN815cJjK5Xe" style="width: 11%; text-align: right" title="Concentration credit risk percentage"><p style="margin: 0">61</p></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLE6MZkSGs81" style="text-align: right" title="Concentration credit risk percentage"><p style="margin: 0">1</p></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ze0STQXKxDZ1" style="margin: 0" title="Concentration credit risk percentage">0</p></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZg4bz5fHflg" style="text-align: right" title="Concentration credit risk percentage">1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIki8Owy3pLe" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30,<br/> 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBGjTKXwsdgk" style="width: 14%; text-align: right" title="Concentration credit risk percentage">72</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWjCKLY6cQod" style="width: 14%; text-align: right" title="Concentration credit risk percentage">93</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal Agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV7kcl37Goj6" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwLKH9Usn5u1" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A2_z6fKIun8pyv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11114925	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3348046	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18404566	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8019880	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19471057	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10462520	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17629225	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10029068	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	42645903	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32842695	shares
	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	135554	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	32074	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1565798	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96557	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	135554	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	32074	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1565798	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96557	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	83883	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	63638	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	75057	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64393	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	66969	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	51777	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	175750	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65640	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	80906	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	146546	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	282095	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	64310	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	75620	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	45900	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	41700	usd
	us-gaap	Lease Cost LeaseCost	110210	usd
	us-gaap	Lease Cost LeaseCost	117320	usd
CY2023Q2	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	586000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2353536	usd
	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	July, 2020 to June, 2024
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12000000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18175111	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18279186	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1596850	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	455517	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	16578261	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
	us-gaap	Debt Instrument Convertible Conversion Price Decrease DebtInstrumentConvertibleConversionPriceDecrease	2.50
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q2	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	1	usd
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q2	PBIO	Percentage Of Price Rate PercentageOfPriceRate	0.10	pure
CY2023Q2	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.5
CY2023Q2	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.35	pure
CY2023Q2	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.50
CY2023Q2	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	5	integer
CY2023Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	2230028	usd
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1788969	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	171103	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	163175	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1895750	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-05-25
CY2023Q2	PBIO	Non Convertible Debt Instrument Amount NonConvertibleDebtInstrumentAmount	861500	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	150000	usd
CY2023Q2	PBIO	Accrued Interest Rate Percent AccruedInterestRatePercent	0.0375	pure
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	731	usd
	PBIO	Deferred Interest DeferredInterest	14719	usd
	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	1544	usd
CY2023Q2	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	95	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1098	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17586591	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17570591	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2330484	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	117552	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	449168	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19350355	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	18368728	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-029724-index-headers.html	Edgar Link	pending
0001493152-23-029724-index.html	Edgar Link	pending
0001493152-23-029724.txt	Edgar Link	pending
0001493152-23-029724-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex21-1_001.jpg	Edgar Link	pending
ex21-1_002.jpg	Edgar Link	pending
ex21-1_003.jpg	Edgar Link	pending
ex21-1_004.jpg	Edgar Link	pending
ex21-1_005.jpg	Edgar Link	pending
ex21-1_006.jpg	Edgar Link	pending
ex21-1_007.jpg	Edgar Link	pending
ex21-1_008.jpg	Edgar Link	pending
ex21-1_009.jpg	Edgar Link	pending
ex21-1_010.jpg	Edgar Link	pending
ex21-1_011.jpg	Edgar Link	pending
ex21-1_012.jpg	Edgar Link	pending
ex21-1_013.jpg	Edgar Link	pending
ex21-1_014.jpg	Edgar Link	pending
ex21-1_015.jpg	Edgar Link	pending
ex21-1_016.jpg	Edgar Link	pending
ex21-1_017.jpg	Edgar Link	pending
ex21-1_018.jpg	Edgar Link	pending
ex21-1_019.jpg	Edgar Link	pending
ex21-1_020.jpg	Edgar Link	pending
ex21-1_021.jpg	Edgar Link	pending
ex21-1_022.jpg	Edgar Link	pending
ex21-1_023.jpg	Edgar Link	pending
ex21-1_024.jpg	Edgar Link	pending
ex21-1_025.jpg	Edgar Link	pending
ex21-1_026.jpg	Edgar Link	pending
ex21-1_027.jpg	Edgar Link	pending
ex21-1_028.jpg	Edgar Link	pending
ex21-1_029.jpg	Edgar Link	pending
ex21-1_030.jpg	Edgar Link	pending
ex21-1_031.jpg	Edgar Link	pending
ex21-1_032.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbio-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
pbio-20230630_cal.xml	Edgar Link	unprocessable
pbio-20230630_lab.xml	Edgar Link	unprocessable
pbio-20230630_def.xml	Edgar Link	unprocessable
pbio-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q3 Form 10-Q Financial Statement

#000149315223029724 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q3 Form 10-Q Financial Statement

#000149315223029724 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio